Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in EBV-related NPC (Dern)
NCT03923842Phase 2Unknown
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in nasopharyngeal carcinoma (NPC), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Plasmatic EBV DNA change. Status: unknown.
02
Drugs
denosumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03923842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923842.